Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Study To Examine Effect Of CP-866,087 On Consumption And Craving Of Alcohol In Alcohol Dependent Subjects.

This study has been completed.
Information provided by (Responsible Party):
Pfizer Identifier:
First received: September 2, 2005
Last updated: October 1, 2012
Last verified: October 2012
Test the hypothesis that increasing doses of CP-866,087 will decrease the total number of drinks consumed during a 2 hour acute alcohol consumption assessment and to determine the safety and tolerability of multiple doses of CP-866,087 in alcohol dependent subjects compared to placebo.

Condition Intervention Phase
Drug: CP-866,087
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: Randomized, Placebo-Controlled Parallel Group Study Comparing Effect Of Three Doses Of CP-866,087 And Naltrexone On Acute Alcohol Consumption And Craving After Seven Days Of Treatment In Alcohol Dependent (DSM IV) Subjects Who Are Not Currently Seeking Treatment

Resource links provided by NLM:

Further study details as provided by Pfizer:

Primary Outcome Measures:
  • The amount of alcohol consumed will be based on the total number of standardized drinks consumed during a two-hour laboratory-based self-administration procedure following 7 days of treatment with study medication.

Enrollment: 88
Study Start Date: December 2003
Study Completion Date: December 2004

Ages Eligible for Study:   21 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subject meets the DSM-IV criterion for current alcohol dependence.
  • Subject is currently not engaged in, and does not want, treatment for alcohol related problems.

Exclusion Criteria:

  • Subject meets criteria for current DSM-IV diagnosis for any other psychoactive substance abuse or dependence disorder, excluding nicotine and caffeine.
  • Specialized inpatient or outpatient alcoholism or other addiction treatment (except nicotine) within the past 12 months.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00147576

United States, California
Pfizer Investigational Site
Cerritos, California, United States, 90703
United States, Connecticut
Pfizer Investigational Site
New Haven, Connecticut, United States, 06504
Pfizer Investigational Site
New Haven, Connecticut, United States, 06519
United States, District of Columbia
Pfizer Investigational Site
Washington, District of Columbia, United States, 20016
United States, Florida
Pfizer Investigational Site
Melbourne, Florida, United States, 32901
Pfizer Investigational Site
Melbourne, Florida, United States, 32935
United States, Kansas
Pfizer Investigational Site
Lenexa, Kansas, United States, 66219
United States, Rhode Island
Pfizer Investigational Site
Providence, Rhode Island, United States, 02908
United States, South Carolina
Pfizer Investigational Site
Charleston, South Carolina, United States, 29425
United States, Texas
Pfizer Investigational Site
San Antonio, Texas, United States, 78229-3900
Pfizer Investigational Site
San Antonio, Texas, United States, 78229
Sponsors and Collaborators
Study Director: Pfizer Call Center Pfizer
  More Information

Responsible Party: Pfizer Identifier: NCT00147576     History of Changes
Other Study ID Numbers: A5051005
Study First Received: September 2, 2005
Last Updated: October 1, 2012

Additional relevant MeSH terms:
Alcohol-Related Disorders
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders processed this record on May 24, 2017